The systemic and renal hemodynamic effects of PLV-2 (octapressin) were studied in patients with hypotension or decompensated cirrhosis of the liver. Low doses (0.004 to 0.02 units/min) increased renal blood flow (indicator-dilution technique), reduced renal vascular resistance, and produced a slight increase in arterial pressure and systemic vascular resistance. Higher doses (0.1 to 0.5 units/min) produced a sharp increase in arterial pressure and systemic resistance while renal resistance increased moderately and renal blood flow usually was maintained above control levels. Renal fraction was increased at all dose levels. The increased renal blood flow was accompanied by more rapid intrarenal dye transit time and slight increase in renal extraction ratio of paraaminohippurate suggesting a rise in cortical blood flow. It is concluded that PLV-2 in small doses produces renal vasodilatation and in larger doses preferential extra-renal vasoconstriction resulting in redistribution of blood flow to the kidney.
ported to be a dependable and apparently well-tolerated pressor agent,6-8 its clinical use has been limited mostly to the management of bleeding esophageal varices on the basis of its splanchnic vasoconstrictor activity. 9 In the present study it has been found that PLV-2 has the unique property of producing renal vasodilatation combined with systemic vasoconstriction, thus leading to a redistribution of blood flow to the kidney. It is suggested that the vascular effects of the drug may have potential therapeutic application when hypotension and renal hypoperfusion coexist. COHN Average values in eight patients given both low and high dose infusions of PLV-2.
Stroke volume was not significantly altered. Venous pressure measured in the renal vein, inferior vena cava, or right atrium showed only negligible and inconsistent changes.
Renal Hemodynamic Effects
Intravenous infusion of PLV-2 in a dose of approximately 0.004 units/min produced a slight increase in arterial pressure and a rise in RBF ( fig. 1 ). In one patient renal vasodilatation occurred with a dose insufficient to alter blood pressure. As the dose was increased, the pressor effect became more marked and RBF fell, although in many patients it remained higher than in the control period.
For purposes of analysis the responses to intravenously administered PLV-2 were divided into low dose effects (0.004 to 0.02 units/min) and high dose effects (0.1 to 0.5 units/min). Low doses of PLV-2 produced an increase in renal blood flow (RBF) and a decrease in renal vascular resistance (RR) ( shortened by PLV-2 in every subject (P < / -+ -~0 . 0 1 ) .
Since RBF was increased and mean transit time was shortened, changes in calculated renal blood volume were not consistent. In six patients volume increased during PLV-2 infusion, and in the other five subjects it either was not altered or fell slightly.
The renal extraction ratio of para-aminohippurate (PAH) was determined in six patients (table 2) . The average PAH-extraction ratio was 0.51 in the control period; it either remained the same or increased slightly during infusion of PLV-2. Thus, the increase in total renal blood flow during PLV-2 infusion was distributed to tissue which extracted with the smaller doses. However, in seven of 10 subjects, RBF remained higher than in the control period (table 1) . RBF averaged 870 ml/min during high dose infusions compared to a control of 769 ml/min (P > 0.05). MAP was increased an average of 26.2 mm Hg, and RR rose from a control of 8,090 to 9,867 dynesec cm-5 (P <0.05). The RF was increased from 10.6 to 12.9% (P > 0.05) ( fig. 3) .
Eight patients were given both low and high dose infusions ( fig. 2) . In each instance the highest RBF was attained during low dose administration, but in five of the subjects, the RBF attained during administration of high doses still was higher than that in the control period. RR fell during low dose infusion in six of the eight patients and increased above control values during high dose infusion in all but one subject. RF averaged 8.8% in the control period, 13.1% with low doses, and 10.7% with high doses.
Configuration of the renal dye curves was predictably altered by PLV-2. The dye appearance time was shortened by low doses from an average of 3.7 to 2.5 sec (P <0.05), and the time from dye injection to peak con-
Renal Arterial Infusion
In two subjects the renal vasoactive properties of PLV-2 were tested by infusing the drug directly into the renal artery and measuring blood flow in the perfused kidney. In one hypertensive subject an infusion of 0.00003 units/min produced a small, but definite, increase in kidney blood flow from 535 to 621 ml/min/kidney. This very small infusion rate of the drug was associated with a 6-mm Hg rise in MAP and a fall in R-R from 14,355 to 12,945 dyne-sec cm-5. In the other subject (R. W.) a much larger renal arterial infusion of 1 unit/min produced a marked systemic pressor effect without much change in RBF. (fig. 4) . Although CO was slightly higher and total systemic vascular resistance lower during the infusion of norepinephrine, RBF was considerably higher during PLV-2 infusion, and renal resistance was less.
In another subject (H. E.) equipressor doses of angiotensin amide (Hypertensin) and PLV-2 were administered. RBF was 780 ml/min during angiotensin infusion and 1,020 ml/min during PLV-2 infusion. Renal resistance was 9,128 dyne-sec cm-5 during angiotensin infusion and only 6,825 dyne-sec cm-5 during PLV-2 infusion.
Side Effects
Low doses of PLV-2 usually produced no subjective symptoms, although facial pallor indicating cutaneous vasoconstriction often was detectable even with the smallest doses used. With higher infusion rates, skin pallor Circulation, Volume XXXVIII, July 1968 was always evident, and the patients often experienced abdominal cramps and the urge to defecate. None of the patients complained of headache, chest pain, or dyspnea, and the electrocardiogram, when monitored during the infusion, was not altered. No evidence of tachyphylaxis was noted during infusions lasting up to 4 hours.
Discussion
Previous studies with natural and synthetic vasopressin have suggested that they may increase renal blood flow. 5' 11, 12 However, the results have been variable. Synthetic vasopressin increased the RBF in anesthetized cats and rabbits,13 but not in conscious dogs14 or humans.'5 PLV-2, which may have vascular effects qualitatively similar to those of vasopressin,5' 9 13, 16 increased RBF in dogs with hemorrhagic or endotoxin shock,'7 1' but not in normotensive dogs or human subjects.17 Barer13 has concluded that renal vasodilatation following both lysine vasopressin and PLV-2 is peculiar to the anesthetized animal.
In the present study a renal vasodilator effect of PLV-2 was demonstrated consistently in unanesthetized human subjects. Intravenous infusion of small doses of the polypeptide produced slight increases in arterial pressure and in total systemic vascular resistance and led to a sharp increase in RBF and a fall in renal vascular resistance. That the decrease in renal resistance was not merely the passive effect of an increase in arterial pressure is demonstrated by the observation in one subject of an increase in RBF without a change in arterial pressure. Furthermore, direct renal arterial infusion of a very small dose of PLV-2 in one subject also led to a fall in renal vascular resistance.
The 
